Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heinrich Roder

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 29, 2009
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabDavid P Carbone, J Stuart Salmon, Dean Billheimer, et al.
Journal of Mass Spectrometry and Advances in the Clinical Lab|December 11, 2023
Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidanceMatthew A Koc, Timothy Aaron Wiles, Daniel C Weinhold, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 4, 2011
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitorsChiara Lazzari, Anna Spreafico, Angela Bachi, et al.
Cancers|July 2, 2021
Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based TestDevalingam Mahalingam, Leonidas Chelis, Imran Nizamuddin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 21, 2010
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patientsChristine H Chung, Erin H Seeley, Heinrich Roder, et al.
Cancer Immunology Research|December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic MelanomaJeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
The Biochemical Journal|March 7, 2002
A cytochrome c mutant with high electron transfer and antioxidant activities but devoid of apoptogenic effectZiedulla Kh Abdullaev, Marina E Bodrova, Boris V Chernyak, et al.
Cancers|September 9, 2020
Definition and Independent Validation of a Proteomic-Classifier in Ovarian CancerSabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Journal of Pancreatic Cancer|March 31, 2021
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas CancerPeter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|December 29, 2009
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabDavid P Carbone, J Stuart Salmon, Dean Billheimer, et al.
Journal of Mass Spectrometry and Advances in the Clinical Lab|December 11, 2023
Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidanceMatthew A Koc, Timothy Aaron Wiles, Daniel C Weinhold, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 4, 2011
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitorsChiara Lazzari, Anna Spreafico, Angela Bachi, et al.
Cancers|July 2, 2021
Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based TestDevalingam Mahalingam, Leonidas Chelis, Imran Nizamuddin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 21, 2010
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patientsChristine H Chung, Erin H Seeley, Heinrich Roder, et al.
Cancer Immunology Research|December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic MelanomaJeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
The Biochemical Journal|March 7, 2002
A cytochrome c mutant with high electron transfer and antioxidant activities but devoid of apoptogenic effectZiedulla Kh Abdullaev, Marina E Bodrova, Boris V Chernyak, et al.
Cancers|September 9, 2020
Definition and Independent Validation of a Proteomic-Classifier in Ovarian CancerSabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Journal of Pancreatic Cancer|March 31, 2021
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas CancerPeter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, et al.
Pageof 9